Sugi Predict

Sugi Predict / Compounds / SCHEMBL8660

SCHEMBL8660

SCHEMBL8660

CC(c1oc2ccc(Br)cc2c(=O)c1-c1ccccc1F)n1cnc2c(N)ncnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 17/20 0.43
▸ PIK3R1 P27986 6/20 0.43
▸ PIK3CG P48736 1/20 0.40
▸ CSNK1E P49674 1/20 0.40
▸ GABRP O00591 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ GABRB2 P47870 1/20 0.40
▸ GABRA4 P48169 1/20 0.40
▸ GABRE P78334 1/20 0.40
▸ GABRA6 Q16445 1/20 0.40
▸ GABRG1 Q8N1C3 1/20 0.40
▸ GABRG3 Q99928 1/20 0.40
▸ GABRQ Q9UN88 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30670835 1.00 PIK3CD (0.43) PIK3CDPIK3R1PIK3CGCSNK1EGABRP
SCHEMBL7726 0.92 PIK3CD (0.46) PIK3CDPIK3R1PIK3CGCSNK1EADORA2A
SCHEMBL30013556 0.92 PIK3CD (0.46) PIK3CDPIK3R1PIK3CGCSNK1EADORA2A
SCHEMBL17970683 0.91 PIK3CD (0.45) PIK3CDPIK3R1PIK3CGCSNK1EADORA2A
SCHEMBL8382 0.91 PIK3CD (0.46) PIK3CDPIK3R1PIK3CGCSNK1EADORA2A
SCHEMBL30670832 0.91 PIK3CD (0.46) PIK3CDPIK3R1PIK3CGCSNK1EADORA2A
SCHEMBL30670876 0.88 PIK3CD (0.49) PIK3CDPIK3R1PIK3CGCSNK1EADORA2A
SCHEMBL8147 0.88 PIK3CD (0.49) PIK3CDPIK3R1PIK3CGCSNK1EADORA2A
SCHEMBL8597 0.82 PIK3CD (0.53) PIK3CDPIK3R1PIK3CGCSNK1E
SCHEMBL30670872 0.82 PIK3CD (0.53) PIK3CDPIK3R1PIK3CGCSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US claimed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US claimed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP claimed
CN-117222413-A Methods and combinations for treating tumors 同润生物医药(上海)有限公司 2023-12-12 — — CN claimed
WO-2022171121-A1 METHOD AND COMBINATION FOR TREATING TUMORS 同润生物医药(上海)有限公司 2022-08-18 — — WO claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3R1 95/4885PIK3CG 99/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3R1 95/4885PIK3CG 99/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3R1 95/4885PIK3CG 99/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PIK3CD 103/4885PIK3R1 53/4885PIK3CG 126/4885
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 PIK3CD 116/4885PIK3R1 45/4885PIK3CG 221/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3R1 95/4885PIK3CG 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.